What You Ought to Know:
– Phenomix Sciences, a precision medication biotechnology firm that brings data-driven precision medication to weight problems remedy, introduced it has been awarded the primary patent associated to its weight problems phenotyping know-how.
– The patent (No. 11,740,247, titled “Strategies and Supplies for Assessing and Treating Weight problems”) covers strategies for treating weight problems by figuring out phenotypes by way of weight problems analyte signatures and administering interventions, equivalent to medicines based mostly on that signature.
What’s weight problems phenotyping?
Phenotyping classifies your kind of weight problems based mostly on particular organic mechanisms. Understanding which of the 4 phenotypes you’ve pinpoints what’s driving your weight achieve and limiting your capacity to reduce weight. Utilizing weight-loss options particular to your phenotype and genetic make-up can double your weight reduction in comparison with typical strategies.
Precision Drugs and Phenotyping to Deal with Weight problems
The know-how underlying the patent was developed by Phenomix’s founders at Mayo Clinic, Andres Acosta, M.D., Ph.D., and Michael Camilleri, M.D., D.Sc. The patent is assigned to Mayo Clinic and completely licensed to Phenomix to develop, manufacture and market weight problems phenotyping assessments together with the 2 MyPhenomeTM Checks launched by the corporate earlier within the yr.
The newly granted patent was issued from one in every of 4 households of filed patent functions. The patent functions are directed to varied facets of customized weight problems medication, together with foundational weight problems phenotyping know-how, analytical and laptop applied strategies, phenotype-related way of life interventions and particular predictors of drug response. The claims cowl many sorts of analytes, together with gene variants (SNPs), metabolites, gastrointestinal peptides and hormones; questionnaires, and phenotypes that are linked to particular interventions (e.g., pharmacological brokers).
